Get Opto’s best content every day, by subscribing to our FREE Newsletter: www.cmcmarkets.com/en/opto/newsletter
Ali Urman is ARK Invest’s Genomics analyst, responsible for the company’s research on Gene editing, DNA sequencing, Stem cell technologies & Immunotherapy. Spearheaded by one of the most talked-about investors in modern history, Cathie Wood, ARK Invest’s flagship fund received $1.5bn inflows in the first half of 2022, even as a tech sell-off continues to hamper its top holdings.
I last spoke to Ali in November 2021, discussing the basics of DNA sequencing, and its overall potential. This time, we explored the efficacy of gene editing, examining her recent CRISPResso analysis – a method for assessing the efficacy of three major gene editing technologies. For help understanding the ultimate investment potential in Genomics, Ali’s insight is unparalleled. Enjoy!
We reference multiple diagrams throughout, view those here: https://ark-invest.com/newsletters/issue-315/
And listen to my previous interview with Ali, here: https://podcasts.apple.com/gb/podcast/89-ali-urman-ark-invest-dna-sequencing-the-genomic/id1504694129?i=1000541462274
Thanks to Cofruition for consulting on and producing the podcast. Want further Opto insights? Check out our daily newsletter: https://www.cmcmarkets.com/en-gb/opto/newsletter
------------------
Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment, or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction, or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinions on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.